Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

141
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
141
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

321
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
321
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

567
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
567
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

238
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
238
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

26
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
26
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

167
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
167

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.

Journal of hepatology·2025
Same author

Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival.

JHEP reports : innovation in hepatology·2025
Same author

Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis.

JHEP reports : innovation in hepatology·2024
Same author

Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2024
Same author

Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation.

Journal of hepatology·2024
Same author

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

Hepatology (Baltimore, Md.)·2023

Related Experiment Video

Updated: Oct 16, 2025

Laparoscopic Common Bile Duct Exploration Followed by Primary Suture Using a Modified Bile Duct Incision
05:36

Laparoscopic Common Bile Duct Exploration Followed by Primary Suture Using a Modified Bile Duct Incision

Published on: May 2, 2025

307

Practical management of primary biliary cholangitis.

Albert Parés1,

  • 1Hospital Clínic de Barcelona.

Revista Espanola De Enfermedades Digestivas
|October 19, 2021
PubMed
Summary

Primary biliary cholangitis (PBC) is an autoimmune liver disease. This review offers a practical diagnostic and management algorithm for physicians, addressing challenges in treating PBC patients.

Area of Science:

  • Hepatology
  • Autoimmune Diseases
  • Gastroenterology

Background:

  • Primary biliary cholangitis (PBC) is a chronic, autoimmune cholestatic liver disease primarily affecting middle-aged women.
  • Elevated alkaline phosphatase and bilirubin, pruritus, and fatigue are key clinical manifestations, impacting patient quality of life.
  • While ursodeoxycholic acid (UDCA) is standard, up to 40% of patients show inadequate response, necessitating second-line therapies.

Purpose of the Study:

  • To review the main characteristics of Primary Biliary Cholangitis (PBC).
  • To present a practical, user-friendly algorithm for PBC diagnosis and management.
  • To provide guidance based on European Association for the Study of the Liver recommendations.

Main Methods:

  • Review of existing literature and clinical guidelines on PBC.

Related Experiment Videos

Last Updated: Oct 16, 2025

Laparoscopic Common Bile Duct Exploration Followed by Primary Suture Using a Modified Bile Duct Incision
05:36

Laparoscopic Common Bile Duct Exploration Followed by Primary Suture Using a Modified Bile Duct Incision

Published on: May 2, 2025

307
  • Development of a diagnostic and management algorithm by Spanish PBC experts.
  • Algorithm based on European Association for the Study of the Liver recommendations.

    • Main Results:

    • PBC is characterized by autoimmune pathogenesis, cholestasis, and specific biochemical markers.
    • Ursodeoxycholic acid (UDCA) is the first-line treatment, but a significant portion of patients require alternative therapies.
    • Obeticholic acid is an approved second-line option for inadequate responders or UDCA-intolerant patients.

    Conclusions:

    • Primary Biliary Cholangitis (PBC) diagnosis and management remain challenging for clinicians.
    • A practical algorithm can aid physicians in effectively diagnosing and managing PBC patients.
    • Adherence to expert-developed guidelines ensures optimal patient care and treatment strategies.